Fig. 7

Variable dose blocking. JHU-LX48 SCLC PDX bearing mice (n = 3/group, 9 groups, 27 total) were injected (i.v.) first with olaparib (0–50 mg/kg) or talazoparib (0–15 mg/kg). Mice were injected (i.v.) with 200–300 μCi of [¹⁸F]PARPi 30 min later, and imaged via PET/CT 2 h later. a Representative MIPs from 4 different doses each, for olaparib (left) and talazoparib (right). b Quantification of PET images for tumor uptake at each of 4 different doses of olaparib (left) and talazoparib (right), compared to [¹⁸F]PARPi only. c Curve fitting analysis for olaparib (left) and talazoparib (right) showing calculated 50% blocking doses. d Comparison of olaparib and talazoparib at equal doses (left) and at therapeutic doses (right). Non-parametric Student’s t-test was used to calculate the statistics. *P < 0.05; **P < 0.01. Error bars represent the SD